GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (NAS:ATLN) » Definitions » GF Score

ATLN (Atlantic International) GF Score : 34/100 (As of Mar. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Atlantic International GF Score?

Atlantic International has the GF Score of 34, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Atlantic International might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Atlantic International's GF Score

For the Diagnostics & Research subindustry, Atlantic International's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atlantic International's GF Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Atlantic International's GF Score distribution charts can be found below:

* The bar in red indicates where Atlantic International's GF Score falls into.


';

Atlantic International  (NAS:ATLN) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Atlantic International GF Score Related Terms

Thank you for viewing the detailed overview of Atlantic International's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Atlantic International Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
Executives
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801